antilipolytic

Acipimox (K-9321) is a niacin derivative and nicotinic acid analog with activity as a hypolipidemic agent. Acipimox has special application for the treatment of hyperlipidemia in non-insulin-dependent diabetic patients.

2,6-Dimethylpyrazine is an indispensable flavor additive in the food industry and an important substrate for the production of hypoglycemic and antilipolytic compounds.

Zingerone (Vanillylacetone) is a nontoxic methoxyphenol isolated from Zingiber officinale, with potent anti-inflammatory, antidiabetic, antidiarrhoeic, antilipolytic, antispasmodic, and anti-tumor properties. Zingerone (Gingerone) alleviates oxidative stress and inflammation, down-regulates NF-κB mediated signaling pathways, acts as an anti-mitotic agent, and inhibits the growth of neuroblastoma cells.

Ko-3290 is a cardioselective antagonist of β-adrenoceptors known for its antilipolytic effects in animals.

Tizoprolic acid is an antilipolytic compound that also functions to reduce ketone bodies in the bloodstream.

Acipimox (K-9321) sodium, a nicotinic acid analogue, functions as an antilipolytic agent by stimulating leptin release, inhibiting lipolysis, and reducing systemic free fatty acids (FFAs) levels, thereby enhancing insulin sensitivity.